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Abstract
Background: Even in the presence of oxygen, malignant cells often highly depend on glycolysis for energy
generation, a phenomenon known as the Warburg effect. One strategy targeting this metabolic phenotype is
glucose restriction by administration of a high-fat, low-carbohydrate (ketogenic) diet. Under these conditions,
ketone bodies are generated serving as an important energy source at least for non-transformed cells.
Methods: To investigate whether a ketogenic diet might selectively impair energy metabolism in tumor cells, we
characterized in vitro effects of the principle ketone body 3-hydroxybutyrate in rat hippocampal neurons and five
glioma cell lines. In vivo, a non-calorie-restricted ketogenic diet was examined in an orthotopic xenograft glioma
mouse model.
Results: The ketone body metabolizing enzymes 3-hydroxybutyrate dehydrogenase 1 and 2 (BDH1 and 2), 3-
oxoacid-CoA transferase 1 (OXCT1) and acetyl-CoA acetyltransferase 1 (ACAT1) were expressed at the mRNA and
protein level in all glioma cell lines. However, no activation of the hypoxia-inducible factor-1a (HIF-1a) pathway
was observed in glioma cells, consistent with the absence of substantial 3-hydroxybutyrate metabolism and
subsequent accumulation of succinate. Further, 3-hydroxybutyrate rescued hippocampal neurons from glucose
withdrawal-induced cell death but did not protect glioma cell lines. In hypoxia, mRNA expression of OXCT1,
ACAT1, BDH1 and 2 was downregulated. In vivo, the ketogenic diet led to a robust increase of blood 3-
hydroxybutyrate, but did not alter blood glucose levels or improve survival.
Conclusion: In summary, glioma cells are incapable of compensating for glucose restriction by metabolizing
ketone bodies in vitro, suggesting a potential disadvantage of tumor cells compared to normal cells under a
carbohydrate-restricted ketogenic diet. Further investigations are necessary to identify co-treatment modalities, e.g.
glycolysis inhibitors or antiangiogenic agents that efficiently target non-oxidative pathways.
Background
High-grade gliomas are intrinsic brain tumors character-
ized by resistance to apoptotic stimuli, diffuse infiltration
into the surrounding tissue and local immunosuppres-
sion. Despite advances in research on tumor biology and
efforts to promote new therapies, the prognosis for
patients with high-grade gliomas is still poor. Currently
available treatment options for glioblastoma patients,
including surgery, radio- and chemotherapy, result
in a median survival of only about 12 months [1,2].
Obviously, other therapeutic approaches are needed that,
on the one hand, impair tumor cell growth and, on the
other hand, permit an adequate quality of life.
Many malignant cells display high rates of glycolysis
and lactate production, even in the presence of adequate
oxygen, a phenomenon known as aerobic glycolysis or
the Warburg effect [3]. Additionally, tumor hypoxia
results in constitutive upregulation of glycolysis and is
considered to substantially contribute to the resistance
of tumor cells to therapeutic strategies [4,5]. One
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dependent” tumors could be the ketogenic diet. The
classic ketogenic diet is a high-fat and low-carbohydrate
dietetic approach raising levels of serum ketone bodies,
i.e. acetoacetate, 3-hydroxybutyrate (from less than 0.1
mM to 0.2-1.8 mM and 2-5 mM, respectively) and acet-
one, and lowering brain glucose uptake [6-8]. Acetoace-
tate and 3-hydroxybutyrate are almost exclusively
synthesized in the liver from acetyl-CoA that results
from the beta-oxidation of fatty acids. Acetone is
formed from acetoacetate by spontaneous decarboxyla-
tion and is generally considered of little metabolic sig-
nificance. Energy generation from ketone bodies takes
place via the citric acid cycle and oxidative phosphoryla-
tion and therefore requires proper mitochondrial func-
tion. In contrast to glucose, ketone bodies thus bypass
cytoplasmic glycolysis and directly enter the citric acid
cycle as acetyl-CoA. In fasting humans, the water-solu-
ble ketone bodies can supply approaching 60% of the
brain’s energy requirement. Besides being a source of
energy, ketone bodies can provide substrates for anabo-
lism, particularly for the synthesis of lipids such as cho-
lesterol in myelin. A simplified diagram of ketone body
metabolism is shown in Figure 1A. As malignant cells
are thought to depend on glucose as a major source of
energy while having impaired mitochondrial function
[ 9 - 1 1 ] ,ak e t o g e n i cd i e tt h u sm i g h ti n d u c eat u m o r -
s e l e c t i v ee n e r g yd e p r i v a t i on. There has been consider-
able research on the safety, the anticonvulsant and neu-
roprotective effects of the ketogenic diet [8,12,13],
whereas less attention has been paid to its potential for
tumor therapy. Similar to tumors of peripheral tissues
[14], glial tumors were found to have less activity of 3-
oxoacid-CoA transferase 1 (OXCT1), the rate-limiting
enzyme of ketone body degradation, than normal
human white (and gray) matter [15]. Following encoura-
ging observations in two female pediatric patients with
advanced stage malignant astrocytoma who seemed to
benefit from a ketogenic diet [16], a reduction of glioma
growth was noticed in orthotopic mouse models when a
calorie-restricted ketogenic diet was applied [17,18]. A
first clinical study assessing the feasibility and safety of a
non-calorie-restricted ketogenic diet in patients with
recurrent glioblastoma (the ERGO trial, NCT00575146)
revealed good tolerability and suggested some antitumor
activity [19]. Nevertheless, to date, little data concerning
a potential application of a ketogenic diet in brain
tumor treatment is available. So far no randomized con-
trolled trials have been initiated on the ketogenic diet
for tumor therapy. Further, biological effects and asso-
ciated metabolic alterations of a ketogenic diet on
glioma versus neural cells remain to be elucidated. In
the present study, we therefore characterized in vitro
effects primarily of 3-hydroxybutyrate, the major
circulating ketone body, on five human glioma cell lines
(U87MG, U251MG, LNT-229, T98G and A172) and rat
hippocampal neurons and examined the efficacy of a
non-calorie-restricted ketog e n i cd i e ti na no r t h o t o p i c
glioma xenograft mouse model.
Methods
Reagents
Acetoacetate (lithium salt), 3-hydroxybutyrate (sodium
salt), 3-nitropropionic acid, 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT), rotenone,
3-bromopyruvate and PCR primers were purchased
f r o mS i g m a - A l d r i c h( S t .L o u i s ,M O ) ,P o l y F e c t( u s e df o r
transfection of A172 cells) and Attractene (used for
transfection of U87MG, U251MG, LNT-229 and T98G
cells) transfection reagents from Qiagen (Hilden, Ger-
many), recombinant human TRAIL from PeproTech
(Rocky Hill, NJ), temozolomide from Axxora (San
Diego, CA). Antibodies used were anti-ACAT1 (Sigma-
Aldrich), anti-actin (sc1616, Santa Cruz Biotechnology),
anti-BDH1 (Sigma-Aldrich), anti-BDH2 (Sigma-Aldrich),
anti-HIF-1a (BD Transduction Laboratories, San Jose,
C A )a n da n t i - O X C T 1( P r o t e i n T e c h ,C h i c a g o ,I L ) .T h e
3HRE-pTK-luc reporter construct was a kind gift from
J. Pouysségur [20-22]. Acetoacetate is an unstable com-
pound and commercially available only as a lithium salt.
Lithium itself is known to have pleiotropic effects on
diverse cell processes. By contrast, 3-hydroxybutyrate,
the major ketone body in blood, is chemically stable and
provided as a sodium salt. We therefore concentrated
on 3-hydroxybutyrate in most of our experiments.
Cell culture
The human malignant glioma cell lines T98G and
U87MG and NIH-3T3 murine fibroblast cells were
obtained from the American Type Culture Collection
(Manassas, VA). A172, LNT-229 and U251MG cells
were kindly provided by N. de Tribolet (Lausanne, Swit-
zerland). LNT-229 cells expressing a short-hairpin con-
struct for p53 gene suppression (LNT-229 p53sh) and
the corresponding control cells (LNT-229 scrambled sh)
have been described [23]. Glioma cells were maintained
at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s
Medium (4500 mg/L glucose; Sigma-Aldrich) with 10%
fetal calf serum (PAA, Pasching, Austria), 2 mM gluta-
mine, 100 IU/mL penicillin and 100 μg/mL streptomy-
cin. Primary hippocampal neurons and astrocytes from
newborn Wistar rats were prepared as described [24,25].
Unless otherwise indicated, experiments were performed
in serum-free medium containing 5 mM glucose (con-
trol), supplemented with 5 mM acetoacetate (lithium
chloride in the corresponding control) or 5 mM 3-
hydroxybutyrate. For some experiments, glucose was
added to serum- and glucose-free medium to give final
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Figure 1 (A) Simplified diagram of cerebral ketone body metabolism. At times of glucose shortage, such as prolonged fasting, ketone
bodies are an important energy source for the brain. The oxidoreductase 3-hydroxybutyrate dehydrogenase (BDH) mediates the first step of
ketone body degradation, between 3-hydroxybutyrate and acetoacetate. 3-oxoacid-CoA transferase 1 (OXCT1) catalyzes the transfer of coenzyme
A from succinyl-CoA to acetoacetate, generating acetoacetyl-CoA. Via acetyl-CoA acetyltransferase 1 (ACAT1), acetoacetyl-CoA is converted into
two molecules of acetyl-CoA, which then enter the citric acid cycle. The utilization of ketone bodies results in an elevation of intracellular
succinate, leading to HIF-1a stabilization via product inhibition of prolyl hydroxylases (PHD). Furthermore, ketone bodies provide substrates for
the synthesis of various molecules, especially lipids. In this regard, acetoacetyl-CoA is formed in the cytoplasm from acetoacetate by the action
of acetoacetyl-CoA synthetase (AACS). (B) The expression of the ketone body metabolizing enzymes was analyzed in five glioma cell lines as
well as in normal brain (gray, gray matter; white, white matter) by real-time quantitative PCR. Results are presented as the fold change in gene
expression normalized to the internal control 18S rRNA (mean and standard deviation; n.d., not detectable).
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Page 3 of 17concentrations of 0, 1, 2.5, 5, 10 and 25 mM. For
hypoxic conditions, cells were cultured in a Binder
CB53 incubator (Binder, Tuttlingen, Germany). With
institutional review board approval (University Cancer
Center Frankfurt), specimens of normal human gray and
white matter were collected and stored at -80°C until
RNA extraction.
Growth and viability assays
Cell density was assessed using crystal violet staining,
resolubilizing the dye in 0.1 M sodium citrate and mea-
suring the absorbance at 560 nm (Multiskan™ EX,
Thermo Scientific, Langenselbold, Germany). In some
experiments, cell viability was analyzed by MTT reduc-
tion assay [26]; formazan crystals were dissolved in
dimethyl sulfoxide and the absorbance was read at 595
nm. For the evaluation of cell proliferation, incorpora-
tion of bromodeoxyuridine (BrdU) was determined
according to the manufacturer’s instructions (BrdU Cell
Proliferation ELISA, Roche Diagnostics, Mannheim,
Germany). Clonogenic survival assays were performed
by seeding 500 cells in 6-well plates and exposing them
to temozolomide for 24 h, followed by further observa-
tion in drug-free medium containing 5 mM glucose, 5%
fetal calf serum (control) and 5 mM 3-hydroxybutyrate.
After crystal violet staining, colonies of more than 50
cells were counted [27].
Determination of glucose, lactate and 3-hydroxybutyrate
Glucose and lactate concentrations of cell-free superna-
tants were measured on a Hitachi 917 analyzer (Roche
Diagnostics). For the assessment of 3-hydroxybutyrate
levels, a Precision Xtra
R monitoring system (Abbott
Laboratories, Abbott Park, IL) was used.
SDS-PAGE and immunoblotting
For the preparation of protein extracts, cells were har-
vested and lysed in a buffer containing 50 mM Tris-
HCl, 120 mM NaCl, 5 mM EDTA, 0.5% Nonidet-P40, 2
μg/mL aprotinin, 10 μg/mL leupeptin, 100 μg/mL phe-
nylmethylsulfonyl fluoride, 50 mM NaF, 200 μM NaVO5
and phosphatase inhibitor cocktails I and II (Sigma-
Aldrich). Protein concentrations were determined using
a Bradford assay (Bio-Rad, Hercules, CA). Equal
amounts of total protein were fractionated under redu-
cing conditions by sodium dodecyl sulfate polyacryla-
mide gel electrophoresis (SDS-PAGE) and electroblotted
on nitrocellulose (Amersham, Braunschweig, Germany).
Membranes were blocked in Tris buffered saline con-
taining 5% skim milk and 0.1% Tween-20 and incubated
with the appropriate primary and secondary antibodies.
Immune complexes were detected by enhanced chemilu-
minescence (Pierce, Rockford, IL).
Real-time quantitative PCR
Total RNA was extracted using TRIzol™ (Invitrogen,
Carlsbad, CA) and the RNeasy™ system (Qiagen), cDNA
was generated with SuperScript VILO™ (Invitrogen).
Real-time PCR was performed in triplicate reactions using
ABsolute™ Blue QPCR SYBR Green Fluorescein Mix
(Thermo Fisher Scientific, Waltham, MA) and the iQ5
real-time PCR detection system (BioRad, Munich, Ger-
many). Gene expression was calculated relative to the
internal control 18S ribosomal RNA (iQ5 software,
BioRad). Human-specific primer sequences: 18S rRNA,
forward 5’-CGGCTACCACATCCAAGGAA-3’, reverse
5’-GCTGGAATTACCGCGGCT-3’,A A C S ,f o r w a r d5 ’-AC
TGCAGAATCAACCCCAAG-3’, reverse 5’-TTGCCGTT
GAGCGTATACAA-3’,A C A T 1 ,f o r w a r d5 ’-GGAGAG-
CATGTCCAATGTTCC-3’, reverse 5’-CGTCCTGTTCA
TTTCGTGCAA-3’, BDH1, forward 5’-TGGTTTTGGAA
CCACCGGGAGGA-3’, reverse 5’-GCTCCGCCGCACT
GGCATAA-3’, BDH2, forward 5’-GGCCGCTGCT
CAGGGGATTG-3’, reverse 5’-ACGGCTGCCTTGGT
TGTGCT-3’,G L U T 1 ,f o r w a r d5 ’-GATTGGCTCCTTCT
CTGTGG-3’, reverse 5’-TCAAAGGACTTGCCCAGTT
T-3’,M C T 4 ,f o r w a r d5 ’-ATTGGCCTGGTGCTGCTG
ATG-3’, reverse 5’-CGAGTCTGCAGGAGGCTTGTG-3’
[ 2 8 ] ,O X C T 1 ,f o r w a r d5 ’-CACCAGTGCTCATCGCC
ATA-3’, reverse 5’-CACATAGCCCAAAACCACCAA-3’,
VEGF, forward 5’-CTACCTCCACCATGCCAAGT-3’,
reverse 5’-ATGTTGGACTCCTCAGTGGG-3’. Rat-speci-
fic primer sequences: 18S rRNA, forward 5’-GTTGGTT
TTCGGAACTGAGGC-3’, reverse 5’-GTCGGCATCGTT-
TATGGTCG-3’, AACS, forward 5’-ACCGGCTCGC
CACTGAAAGC-3’, reverse 5’-ATGGAGCCGAGGAG-
CACGGT-3’,A C A T 1 ,f o r w a r d5 ’-GGGCTTCCGCCG
TGCTGATT-3’, reverse 5’-CAGCGGGTCACGTG-
GAACTGT-3’, BDH1, forward 5’-GTCAGACGAGCG-
CACCGGTC-3’, reverse 5’-GGCCAGCATCATGGC
ACCGA-3’, BDH2, forward 5’-AGGTCGCCCTGC
TCTGCGTA-3’,r e v e r s e5 ’-GCTCACCCGGCCAGTT
TGCT-3’,O X C T 1 ,f o r w a r d5 ’-AGCCCGGAGAAGA
CGTCAGGG-3’,r e v e r s e5 ’-ATGCGCATTCCCCTTT
GCGGAG-3’.
Luciferase reporter assay
Cells were transiently transfected with a 3HRE-pTK-luc
firefly and, for normalization of transfection efficiency, a
pRL-CMV renilla luciferase construct. Luciferase activity
was assayed using a dual luciferase reporter assay system
[29] and an Infinite
R M200 PRO microplate reader
(Tecan, Maennedorf, Switzerland).
Invasion and migration assays
Matrigel invasion assays were performed as described
previously with some modifications [30]. Transwell
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Page 4 of 17chambers (12 mm diameter, 8 μm pore size, Corning
Costar, Acton, MA) were precoated with 10 μg/cm
2
Matrigel (Matrigel™ Basement Membrane Matrix, BD
Biosciences, Bedford, MA); NIH-3T3-conditioned med-
ium was used as a chemoattractant. Following 12 h
incubation, migrated or invaded cells were fixed, stained
and counted by microscopic examination.
Animals and diets
A l la n i m a lw o r kw a sp e r f o r m e di na c c o r d a n c ew i t ht h e
National Institutes of Health guidelines Guide for the
Care and Use of Laboratory Animals and institutional
standards. 24 female 8-10 week-old athymic mice
(Foxn1nu, Harlan, Indianapolis, IN) were maintained in
groups of 6 animals per cage in a pathogen-free envir-
onment and given ad libitum access to food and water.
O nd a y0o ft h ee x p e r i m e n t ,1 0
5 human LNT-229
glioma cells were stereotactically implanted into the
right striatum. Following recovery from surgery (day 1),
animals were randomized into two diet groups, a stan-
dard diet rich in carbohydrates versus a ketogenic diet.
The standard diet was provided by the animal feed man-
ufacturer ssniff Spezialdiaeten GmbH (Soest, Germany),
the ketogenic diet was kindly supplied by J.F. Coy
(Tavarlin AG, Darmstadt, Germany; [31]). Diet charac-
teristics are summarized in Table 1. Animal body weight
was measured twice weekly. Neurological symptoms
were assessed daily by modified neurological scores
(grade 0: normal; grade 1: tail weakness or tail paralysis;
grade 2: hind leg paraparesis or hemiparesis; grade 3:
hind leg paralysis or hemiparalysis; grade 4: complete
paralysis (tetraplegia), moribund stage or death). Ani-
m a l sw e r ek i l l e da tt h eo n s e to fn e u r o l o g i c a ls y m p t o m s
equal or worse than grade 2.
Magnetic resonance imaging (MRI)
Imaging was performed in prone position on days 37
and 65 after tumor cell implantation using a 3-Tesla
MRI scanner (Trio
R, Siemens, Erlangen, Germany), a
circular polarized wrist coil and 0.5 mmol/mL gadoli-
nium-diethylenetriaminepentaacetic acid (Magnevist
R,
Bayer Schering Pharma, Berlin, Germany). After intra-
peritoneal injection of 0.3 mL/animal, standard T2-
weighted and T1-weighted sequences were acquired.
Determination of blood glucose, blood 3-hydroxybutyrate
and serum IGF-1
Blood glucose and 3-hydroxybutyrate levels were mea-
sured on the day of tumor cell implantation and every 7
days thereafter using 2 μL of peripheral blood from the
tail vein and a Precision Xtra
R monitoring system.
Mouse serum IGF-1 concentrations were analyzed by
immunoassay (Quantikine
R, R&D Systems, Minneapolis,
MN).
Histology/Immunohistochemistry
Mouse brains were formalin-fixed and paraffin-
embedded. 4 μm thick sections were cut and deparaffi-
nation procedures were performed according to stan-
dard protocols. Hematoxylin and eosin stainings were
analyzed by an experienced investigator (PNH). Immu-
nohistochemistry was carried out using a monoclonal
mouse antibody against human Ki67-antigen (clone
MIB-1, Dako, Glostrup, Denmark) and the Ventana Dis-
covery IHC System (Ventana, Strasbourg, France).
Nuclear staining was scored as positive. Five randomly
picked fields (3.7 mm
2) per specimen were evaluated.
Metabolic mapping using bioluminescence imaging
The technique of bioluminescence imaging allows for the
spatial and quantitative detection of key metabolites of
energy metabolism in cryosections of human or animal
tissues [32,33]. Briefly, heat-inactivated cryostat sections
prepared from rapidly frozen brains (three animals per
diet group) were immersed into an enzyme solution
using a temperature-controlled chamber placed on a
microscope stage. The solution contains enzymes that
link the metabolite of interest, i.e. ATP, glucose or lac-
tate, to bacterial or firefly luciferase. Subsequently, the
induced light emission was registered by a photon
detecting video system (Andor EMCCD DU888, BFI-
Optilas, Munich, Germany) connected to the micro-
scope (Axiophot, Zeiss, Oberkochen, Germany). The
registered intensity values are proportional to the local
metabolite concentrations. Therefore, the resulting digi-
tal images could be calibrated [μmol/g] using appropri-
ate tissue standards that were processed in the same
way as the brain sections. Such distributions could be
displayed routinely as color-coded images. Average con-
centration values were acquired in designated tumor
regions and normal tissue using digital overlay of the
metabolite distributions with images from parallel cryo-
sections stained with hematoxylin and eosin.
Table 1 Composition of the standard and ketogenic diets
Component Control, standard diet Ketogenic diet
Fat 6.1 35.5
Carbohydrate 55.6 0.2
Protein 21.8 13.0
Fiber 3.8 14.8
Ashes 5.3 2.1
Energy [kJ/g] 15.8 15.4
Ketogenic ratio 0.08:1 2.7:1
Components of the diets used are listed in grams per 100 grams of food. The
fat in the standard diet derived from soybean oil; the fat source of the
ketogenic diet consisted of a mixture of vegetable oils from flaxseed and
hempseed with elevated levels of omega-3 fatty acid and medium-chain
triglycerides [31]. The ketogenic ratio was calculated according to the
following formula: Fats/(Protein + Carbohydrates).
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In vitro experiments were performed at least three times
with similar results. Data analysis was carried out with
SPSS version 17.0 (IBM SPSS, Chicago, IL). Significance
was tested using the two-tailed Student’s t-test. Synergy
was assessed by the fractional product method [34]. Sur-
vival was estimated by Kaplan-Meier analysis, and differ-
ences were tested by Mantel-Cox log-rank statistics.
Results
Ketone body metabolizing enzymes are expressed in the
five glioma cell lines both at the mRNA and the protein
level. First, we examined whether the five glioma cell
lines express key enzymes involved in ketone body
metabolism. U87MG, U251MG, LNT-229, T98G and
A172 cells exhibited expression of 3-hydroxybutyrate
dehydrogenase (BDH), 3-oxoacid-CoA transferase
(OXCT1), acetyl-CoA acetyltransferase (ACAT1) and
acetoacetyl-CoA synthetase (AACS) at the mRNA (Fig-
ure 1B) and the protein level (Figure 3B). No consistent
change in expression was observed following exposure
to 3-hydroxybutyrate for 24 h or 48 h (Figure 3B and
data not shown). In rat hippocampal neurons, the
expression of these enzymes was confirmed by real-time
quantitative PCR (data not shown).
3-hydroxybutyrate protects primary rat hippocampal
neurons but not human glioma cell lines against glucose
deprivation-induced cell death. Having confirmed the
expression of ketone body metabolizing enzymes, we
assessed whether 3-hydroxybutyrate could serve as an
alternative energy source under conditions of reduced
glucose availability. For this purpose, rat hippocampal
neurons or glioma cells were incubated in the absence
or presence of 5 mM 3-hydroxybutyrate in serum-free
medium containing different glucose concentrations
(hippocampal neurons: 0 mM, 1 mM, 2 mM or 5 mM;
glioma cell lines: 0 mM, 1 mM, 2.5 mM, 5 mM, 10 mM
or 25 mM), and cell density was analyzed by MTT assay
(Figure 2A-B) or crystal violet staining (Figure 2C). Pri-
mary rat hippocampal neuron sb e n e f i t e df r o mt h ep r e -
sence of 3-hydroxybutyrate by prolonged survival under
glucose deprivation. By contrast, in no glioma cell line, a
rescue from glucose withdrawal-induced cell death by
this ketone body was detectable. In untransformed pri-
mary rat astrocytes, some advantage of 3-hydroxybuty-
rate supplementation was evident, although to a lesser
extent than in primary rat hippocampal neurons (Figure
2D).
Ketone bodies do not alter growth or proliferation of
glioma cell lines. Next, we analyzed potential effects of
ketone bodies on cell growth and proliferation in the
presence of sufficient glucose. In all glioma cell lines
tested, the presence of ketone bodies, i.e. acetoacetate,
3-hydroxybutyrate, or both, did not alter cell density at
different time points up to 84 h after exposure (Table 2
and data not shown). Furthermore, cell proliferation as
assessed by BrdU-uptake was unaffected by 3-hydroxy-
butyrate (data not shown). As glucose availability has
been demonstrated to be relevant for cellular survival
under hypoxic conditions [35-37], we investigated
whether hypoxia might alter the deficiency of glioma
cells to metabolize ketone bodies. However, at different
oxygen (21%, 1% or 0.1% O2) or glucose concentrations,
offering 3-hydroxybutyrate did not influence cell density
(Table 2 and data not shown). Furthermore, the pre-
sence of 3-hydroxybutyrate did not modify glucose con-
sumption or lactate generation of the glioma cell lines
examined (analyzed up to six days after exposure; Addi-
tional file 1, Figure S1). Because 3-hydroxybutyrate
might be metabolized for cellular processes which
would not directly be reflected by differences in glucose
consumption, 3-hydroxybutyrate levels were measured
in cell culture supernatants. Only a marginal decrease in
3-hydroxybutyrate in the glioma cell culture superna-
tants was observed (between 0.0 mM and 0.5 mM; ana-
lyzed for up to six days after exposure), indicating no
substantial utilization of this additional energy source.
In cultures of rat hippocampal neurons, 3-hydroxybuty-
rate supernatant concentrations were reduced to a
greater extent despite lower cell densities (1.3 mM
decrease after three days of exposure). A loss of p53
function has been shown to result in metabolic altera-
tions such as reduced cellular respiration, increased glu-
cose consumption and lactate production [38].
Therefore, we examined whether antagonizing p53
would modulate the metabolism of 3-hydroxybutyrate.
However, cell density of both p53 wild-type LNT-229
cells and of LNT-229 cells depleted of p53 by stable
shRNA expression (LNT-229 p53sh) did not differ in
the absence or presence of 3-hydroxybutyrate (Table 2
and data not shown), indicating no induction of ketone
body metabolism by inhibition of p53 function.
Exposure to 3-hydroxybutyrate does not modulate
glioma cell motility and invasiveness. The infiltrative
behavior of malignant glioma cells is a function of two
phenotypes, migration and invasiveness. Migration refers
to the capacity of locomotion whereas invasion involves
migration plus a degradative function achieved by the
liberation of proteolytic enzymes. Using classical migra-
tion and matrigel invasion assays, we did not detect any
significant changes when 3-hydroxybutyrate was offered
(Table 3).
Treatment with 3-hydroxybutyrate does not modify the
expression of hypoxia-inducible factor-1a (HIF-1a)a n d
of its target genes. Human and murine solid tumors are
characterized by hypoxic areas with intratumoral pO2
values between 2 and 12 mmHg (approximately 0.3% -
2% O2; [39-41]). We therefore looked at the expression
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Page 6 of 17of ketone body metabolizing enzymes under hypoxia
(1% or 0.1% O2) as well. Regardless of the absence or
presence of 3-hydroxybutyrate, we noticed a consider-
able downregulation of BDH, OXCT1 and ACAT1
mRNA levels in all cell lines (Figure 3A and data not
shown) in hypoxia. At 24 h after 3-hydroxybutyrate
exposure, this downregulati o nw a sv i s i b l eo np r o t e i n
level primarily in U251MG cells (Figure 3B). Succinate
is generated during the activation of acetoacetate to
acetoacetyl-CoA by the enzyme OXCT1. Accumulation
of succinate can result in the stabilization of HIF-1a via
product inhibition of prolyl hydroxylase (PHD) enzymes
[42]. The small amounts of 3-hydroxybutyrate which
might be metabolized by glioma cells (between 0.0 mM
and 0.5 mM decrease in supernatant level; see above)
could modulate HIF-1a expression as an indirect hint
for ketone body degradation. However, in these cell
lines, 3-hydroxybutyrate did not induce an elevation of
HIF-1a protein (Figure 3B). Similarly, we did not
observe a rise in HRE reporter gene activity (Figure 3C)
or in expression of the HIF-1a target genes GLUT1,
VEGF and MCT4 (Additional file 2, Figure S2, and data
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Figure 2 3-hydroxybutyrate protects neonatal rat hippocampal neurons from cell death induced by glucose deprivation. Neonatal rat
hippocampal neurons (A) or LNT-229 glioma cells (B) were cultured at different glucose concentrations in the absence (control) or presence of
3-hydroxybutyrate (3OHB, 5 mM). MTT reduction was determined 120 h (hippocampal neurons) or 72 h (LNT-229) after exposure (mean and
standard deviation, ** p < 0.01). (C) Glioma cells were grown in medium containing 0 mM, 1 mM, 2.5 mM, 5 mM, 10 mM or 25 mM glucose,
supplemented with 3-hydroxybutyrate (3OHB, 5 mM) or not. Cell density was assessed by crystal violet staining at day 1, 2, 3, 4, 6 and 8 after
exposure, as shown here for LNT-229 cells (mean and standard deviation). (D) Primary rat astrocytes were treated similarly and crystal violet
staining was performed at day 2, 4, 6, 8, 10 and 12 (mean and standard deviation). For a clearer arrangement, 10 mM and 25 mM glucose
conditions, showing no difference in cell density between control and 3-hydroxybutyrate supplementation, are not displayed.
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Page 7 of 17not shown) in any of the five glioma cell lines examined.
3-nitropropionic acid (3NPA) is an irreversible inhibitor
of succinate dehydrogenase, leading to elevated succi-
nate levels. As shown in Figure 3D, 3NPA led to an
increase in HIF-1a protein, at least under hypoxic con-
ditions, confirming that HIF-1a is indeed regulated by
succinate. In summary, these results suggest that 3-
hydroxybutyrate does not modulate HIF-1a expression
or activity in the glioma cell lines analyzed, and there-
fore provide additional evidence for a defective ketone
body utilization of glioma cells.
3-hydroxybutyrate does not influence glioma cell sensi-
tivity towards different triggers of cell death. Finally, we
were interested in whether ketosis could change the sus-
ceptibility to different mechanisms of cell death. In
U87MG, U251MG, LNT-229, T98G and A172 cells,
sensitivity to treatment with rotenone, an inhibitor of
mitochondrial respiratory chain complex I, or 3-bromo-
pyruvate, a synthetic brominated derivative of pyruvic
acid inhibiting the enzyme hexokinase II, was not
altered in the presence of 3-hydroxybutyrate (Figure 4A-
B and data not shown). Moreover, 3-hydroxybutyrate
did not modify cell death induction by activation of the
mitochondrial apoptotic pathway via tumor necrosis fac-
tor-related apoptosis-inducing ligand (TRAIL; Figure 4C
and data not shown), or inhibition of clonogenic cell
growth by temozolomide, the adjuvant standard of care
chemotherapeutic agent in glioma patient treatment
(Figure 4D and data not shown). In all five glioma cell
lines examined, neither synergistic nor antagonistic
effects of 3-hydroxybutyrate were detected.
The ketogenic diet is well accepted and induces stable
ketosis in vivo, but does not affect tumor growth or survi-
val. In a translational approach, the present study aimed
to assess some characteristics of an unrestricted keto-
genic diet similar to the one offered to patients in the
pilot study carried out in our department
(NCT00575146). Using the same ketogenic diet, Otto et
al. had observed a delayed growth of subcutaneously
implanted tumors of the gastric adenocarcinoma cell
line 23132/87 [31]. After ruling out major tumor-sup-
porting effects of ketone bodies in vitro, we performed
an orthotopic xenograft mouse model experiment to
assess whether this ketogenic diet might result in a
tumor-selective energy deficit and thus reduce tumor
growth in vivo. After orthotopic inoculation of LNT-229
glioma cells, mice were randomized into two non-cal-
o r i e - r e s t r i c t e dd i e tg r o u p s ,as t a n d a r dd i e tg r o u pa n da
ketogenic diet group. All animals readily accepted the
unrestricted ketogenic diet. Similar to the findings of
other studies [18,31], their body mass did not differ sub-
stantially from those of control animals (Figure 5A).
Table 2 Growth curves in glioma cells exposed to vehicle or ketone bodies
21% O2 3OHB AcAc LiCl 3OHB + AcAc 3OHB + LiCl
U87MG 94.9 ± 9.9 109.7 ± 10.3 104.5 ± 11.7 107.3 ± 10.1 100.8 ± 10.0
U251MG 100.2 ± 5.8 97.4 ± 5.5 97.0 ± 6.9 96.1 ± 5.4 90.2 ± 5.0
LNT-229 98.4 ± 4.7 100.6 ± 3.7 109.5 ± 7.9 104.0 ± 3.6 95.7 ± 4.0
T98G 96.3 ± 4.8 87.6 ± 4.0 91.2 ± 7.8 86.1 ± 5.3 88.0 ± 4.1
A172 97.1 ± 6.0 100.3 ± 5.7 99.9 ± 7.4 84.9 ± 10.7 90.7 ± 5.6
LNT-229 scrambled sh 99.9 ± 9.5 109.2 ± 6.0 103.7 ± 5.3 102.2 ± 6.2 97.5 ± 6.8
LNT-229 p53sh 98.3 ± 5.3 102.3 ± 3.2 96.5 ± 2.4 95.1 ± 2.4 95.0 ± 2.8
0.1% O2 3OHB AcAc LiCl 3OHB + AcAc 3OHB + LiCl
U87MG 97.7 ± 4.9 115.8 ± 5.8 115.2 ± 4.9 108.8 ± 4.2 104.0 ± 5.7
U251MG 96.6 ± 2.7 102.6 ± 5.0 98.1 ± 2.5 92.1 ± 5.4 86.9 ± 3.0
LNT-229 93.6 ± 3.5 103.2 ± 4.9 104.4 ± 3.3 97.0 ± 3.3 91.0 ± 5.1
T98G 98.8 ± 10.1 100.2 ± 9.1 97.3 ± 8.7 101.7 ± 7.3 91.5 ± 9.9
A172 107.9 ± 15.6 93.2 ± 9.2 95.8 ± 7.4 101.0 ± 8.7 91.6 ± 6.8
LNT-229 scrambled sh 99.6 ± 5.4 104.5 ± 4.7 105.4 ± 6.0 98.9 ± 4.6 103.9 ± 8.2
LNT-229 p53sh 94.8 ± 2.5 107.4 ± 4.2 107.6 ± 5.4 102.9 ± 4.0 96.0 ± 4.5
Cells were exposed to 3-hydroxybutyrate (3OHB, 5 mM), acetoacetate (AcAc, 5 mM), lithium chloride (LiCl, 5 mM) or both for 36 h at 21% or 0.1% O2 and
subsequently stained with crystal violet. Data are expressed as percentages (mean and standard deviation) relative to untreated control cells.
Table 3 Effects of 3-hydroxybutyrate on migratory and invasive abilities
U87MG U251MG LNT-229 T98G A172
migration 94.3 ± 7.8 80.7 ± 31.2 98.4 ± 18.6 100.8 ± 5.7 95.6 ± 10.0
invasiveness 121.4 ± 17.0 104.0 ± 18.6 95.3 ± 14.3 111.4 ± 21.8 108.4 ± 9.2
U87MG, U251MG, LNT-229, T98G or A172 cells were exposed to 3-hydroxybutyrate (5 mM) and migration or invasiveness were assessed. Data are expressed as
mean percentages relative to control cultures and standard error of the mean.
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Figure 3 Influence of hypoxia and 3-hydroxybutyrate on the expression of ketone body metabolizing enzymes and the activity of
HIF-1a signaling. (A) LNT-229 glioma cells were cultured in the absence or presence of 3-hydroxybutyrate (3OHB, 5 mM) at 21%, 1% or 0.1%
oxygen for 24 h. mRNA levels of OXCT1, ACAT1, BDH1 and BDH2 were determined by real-time quantitative PCR. Data are presented as the fold
change in gene expression normalized to the internal control 18S rRNA (mean and standard deviation, p < 0.05 compared with normoxic
conditions, asterisks omitted for clarity). (B) Glioma cell lines were treated as in (A), and the expression of HIF-1a, BDH1, BDH2, OXCT1 and
ACAT1 was analyzed by immunoblot. (C) HIF-specific transcriptional activity was examined by luciferase reporter assay (3HRE-pTK-luc construct)
in the absence or presence of 3-hydroxybutyrate (24 h treatment, mean and standard deviation). (D) Glioma cells were incubated for 24 h at the
indicated oxygen conditions in the absence or presence of 3-nitropropionic acid (3NPA, 10 mM), and the expression of HIF-1a was analyzed by
immunoblot.
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Page 9 of 17Blood 3-hydroxybutyrate levels were continuously and
significantly higher in mice fed the ketogenic diet than
in animals on the control diet. By contrast, no relevant
difference in blood glucose values was observed between
the two groups (Figure 5B). Interindividual and intervisit
blood glucose levels varied strongly. Similarly, serum
concentrations of insulin-like growth factor 1 (IGF-1)
were not significantly different between the two diet
groups (Table 4). MRI analysis and observation for
symptom-free survival did not reveal a difference
between the two diet groups regarding tumor size and
survival (Figure 6A). Histological analysis did not show
differences in the proliferation rate (Figure 6B), nor in
size or morphology of the tumors (data not shown).
ATP, glucose or lactate concentrations in normal and
tumor tissues did not differ significantly between the
two diet groups (metabolite concentrations in tumor
areas, mean and standard deviation, μmol/g, ATP: con-
trol, 1.9 ± 0.9, ketogenic diet, 1.9 ± 0.6, glucose: control,
1.6 ± 0.8, ketogenic diet, 2.0 ± 0.8, lactate: control, 19.8
± 5.1, ketogenic diet, 20.9 ± 3.2; Figure 7). Consistent
with the findings of other studies [43,44] but not reach-
ing statistical significance, bioluminescence imaging data
suggested lower glucose and higher ATP and lactate
concentrations in tumors than in corresponding normal
tissues (tumor-to-normal tissue ratio, mean and stan-
dard deviation, ATP: 1.59 ± 0.91, glucose: 0.88 ± 0.12,
lactate: 1.29 ± 0.55).
Discussion
Strategies specifically targeting the altered metabolic
pathways of tumors are increasingly receiving attention
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Figure 4 The presence of 3-hydroxybutyrate does not modify the sensitivity of LNT-229 cells to inhibitors of oxidative
phosphorylation, glycolysis, TRAIL or temozolomide. LNT-229 cells (mean and standard deviation) were treated with increasing
concentrations of (A) rotenone (48 h), (B) 3-bromopyruvate (150 min) or (C) TRAIL (24 h). In the 3-bromopyruvate experiments, cells were
preincubated in medium containing 3-hydroxybutyrate (3OHB, 5 mM) or not. Cell density was evaluated by crystal violet staining (A, B) or MTT
reduction (C). (D) LNT-229 cells were exposed to temozolomide for 24 h, followed by further observation in drug-free medium supplemented
with 3-hydroxybutyrate (3OHB, 5 mM) or not, and clonogenic survival was analyzed (mean and standard deviation).
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Page 11 of 17[45,46]. In contrast to new chemotherapeutic
approaches, altering diet is perceived by many as an
easy option to delay tumor progression with few side
effects. To the best of our knowledge, however, no ran-
domized clinical trials have been initiated on ketogenic
diets for therapy in any tumor type. Concerning nutri-
tion, patients see themselves faced with incomplete
information and contradictory, sometimes extreme
recommendations. Given the principle of primum nil
nocere, we therefore considered it reasonable and neces-
sary to preclinically evaluate effects of dietary changes
just like those of other anticancer drugs.
Cerebral ketone body metabolism depends on (i) con-
centrations in blood, (ii) the transport across the blood-
brain barrier and into cells and (iii) the activity of
ketone body metabolizing enzymes [6]. Blood concentra-
tion is considered the most important factor affecting
the rate of cerebral ketone body metabolism. As the
blood-brain barrier is relatively impermeable to most
hydrophilic substances, transporters for short-chain
monocarboxylic acids (MCTs, SLC16 family [47]), such
as ketone bodies and lactate, are needed and govern
access of acetoacetate and 3-hydroxybutyrate to central
nervous system tissues [48]. Ketone body entry into
brain cells occurs by diffusion (at a moderately high
rate) and carrier-mediated processes (MCTs; probably
less regulated). Finally, ketone body metabolism depends
on the activities of the relevant enzymes, but due to the
limited number of studies [49], sufficient information
concerning those enzymes in humans is not available.
Table 4 Murine serum IGF-1 concentrations during the ketogenic diet
days post tumor cell implantation
14 24 38 65-115
control KD control KD control KD control KD
animals 4 4 3 3 3 3 10 9
IGF-1 [ng/mL] 245.0
± 50.3
310.3
± 36.8
310.0
± 28.9
417.5
± 106.1
312.7
± 84.9
301.9
± 36.5
242.8
± 53.2
292.2
± 58.1
After LNT-229 tumor cell implantation at day 0, animals were randomized into two diet groups, a standard diet versus a ketogenic diet (day 1). On days 14,2 4
and 38 as well as at the end of the experiment (days 65-115), serum was obtained by centrifugation of whole blood at 2000 g for 10 min and subsequently
stored at -80°C. Murine IGF-1 serum levels determined by immunoassay were not significantly different between diet groups (KD, ketogenic diet; mean and
standard deviation).
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Maurer et al. BMC Cancer 2011, 11:315
http://www.biomedcentral.com/1471-2407/11/315
Page 12 of 17We here demonstrate a deficient utilization of the
major ketone body 3-hydroxybutyrate by human malig-
nant glioma cells. 3-hydroxybutyrate did not alter cell
density or proliferation and could not protect the
human glioma cell lines examined against glucose depri-
vation. By contrast, this ketone body conferred
protection from glucose withdrawal-induced cell death
in primary rat hippocampal neurons (Figure 2). A recent
study using organotypic rat hippocampal slice cultures
supports this observation [50], being in accordance with
the capability of rats to metabolize ketone bodies
[51,52]. Neuroprotective effects of 3-hydroxybutyrate on
A ATP
B glucose
C lactate
D hematoxylin-eosin
control ketogenic diet
Figure 7 Metabolic mapping does not reveal significant differences between the two diet groups. Adjacent cryosections were used for
hematoxylin-eosin staining (D) and for bioluminescence imaging of ATP (A), glucose (B) and lactate (C). Concentration distributions of these
metabolites are color-coded [μmol/g].
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Page 13 of 17primary spinal cord neurons from SODI-G93A mice and
on SH-SY5Y human dopaminergic neuroblastoma cells
exposed to the complex I inhibitor rotenone have also
been described [53,54]. In our experiments, no protec-
tive effect of 3-hydroxybutyrate on glioma cell death
induced either by rotenone or by the glycolysis inhibitor
3-bromopyruvate was detectable (Figure 4A-B). Hence,
in those cell lines, this ketone body could not compen-
sate for energy depletion induced by disturbance of the
mitochondrial respiratory chain or glycolysis. Further,
we did not observe proapoptotic effects of ketone bodies
in glucose-free medium as did Skinner et al.u s i n gt h e
human neuroblastoma cell line SK-N-AS [55], indicating
that this effect might be cell type specific. An increase
in HIF-1a protein levels caused by accumulation of suc-
cinate and inhibition of PHD enzymes (see Figure 1A)
has been described in diet-induced ketotic as well as in
3-hydroxybutyrate-infused rat brain [56] and would
probably be a rather unwanted effect regarding tumor
treatment [57,58]. We therefore evaluated expression,
transcriptional activity and target gene modulation of
HIF-1a. However, neither was affected by 3-hydroxybu-
tyrate (Figure 3 B-C; Additional file 2, Figure S2), sug-
gesting that this ketone body is not metabolized in the
glioma cell lines examined. Furthermore, 3-hydroxybuty-
rate did not influence the migratory behavior of the
glioma cell lines (Table 3). By contrast, it has been
observed that 3-hydroxybutyrate like lactate may func-
tion as a chemoattractant, stimulating the migration of
MDA-MB-231 human breast cancer cells in vitro [59].
Together, our in vitro experiments did not indicate
any ketone body metabolizing activity of the glioma cell
lines examined, a finding which contrasts the protective
effect of 3-hydroxybutyrate on rat hippocampal neurons.
The observed phenotype is probably not caused by defi-
cient expression of monocarboxylic acid transporters
(Additional file 2, Figure S2, [60]) or ketone body meta-
bolizing enzymes (Figure 1B). Both neurons and astro-
cytes are in principle capable of using ketone bodies as
metabolic fuels [61-63]. In tumors, citric acid cycle
metabolism is supposed to be intact and important for
their ability to synthesize substrates for membranes,
nucleic acids and proteins [64,65]. In our experiments,
the accumulation of HIF-1a observed after treatment
with 3NPA also indicates an intact citric acid cycle in
the glioma cell lines (Figure 3D). Other studies on
malignant gliomas demonstrated reductions in electron
transport chain activities [11], structural defects [10,66]
and DNA mutations [67] in mitochondria. Nonetheless,
glioma cells have been shown to exhibit [10] and be
able to modulate respiratory activity [68]. Therefore the
basic requirements for energy yield from ketone bodies
(enzyme equipment, intact citric acid cycle and respira-
tory chain) should be met. Alternatively, the 3-
hydroxybutyrate offered could have been used primarily
for the synthesis of lipids, but in this case a decrease in
supernatant concentrations and perhaps an effect on
proliferation would have been expected. However, the
pure presence of a protein does not imply its proper
function and we didn’t analyze activities of ketone body
metabolizing enzymes in the present study. In an analy-
sis of various tumors and tissues of the nervous system,
OXCT1 enzyme activity was found to be lower in glial
tumors compared to normal human brain [15]. So
enzyme activity could be the factor limiting ketone body
metabolism [6,18]. Taken together, we observed a lack
of capability to degrade ketone bodies in the glioma cell
lines. The deficiency in metabolizing ketone bodies
might indeed represent a characteristic of malignant
transformation, but the underlying defect remains
unclear.
A reduction of tumor growth under conditions of
caloric restriction and/or weight loss has repeatedly
been shown in glioma models [17,18]. However, we
rarely observe chemotherapy-associated (unintended)
weight loss in brain tumor patients and a non-calorie-
restricted ketogenic diet might be more easily realized
than calorie restriction. We therefore performed an in
vivo experiment using an unrestricted ketogenic diet.
The diet was well accepted, and no significant differ-
ences developed in body weight between the two diet
groups (Figure 5A). Further, glucose concentrations and
IGF-1 levels did not differ substantially between the
groups (Figure 5B,Table 4). These results are consistent
with prior analyses showing no decline in blood glucose
concentrations when a ketogenic diet was administered
in unrestricted amounts [18,31,69]. According to other
studies [17,69,70], a reduction in circulating IGF-1 levels
would have been expected only under conditions of
caloric restriction. Thus, the stable values of body mass,
glucose and IGF-1 help to distinguish between possible
starvation-associated effects and other metabolism-spe-
cific effects of the ketogenic diet. Finally, the ketogenic
diet alone did not influence tumor growth in the glioma
model used (Figure 6A); tumor histopathology and
metabolic mapping revealed no differences between
mice fed the ketogenic diet and control animals (Figure
7). Although these results are consistent with those
obtained in other syngeneic (CT-2A) and xenogeneic
(U87MG) glioma mouse models [18], they contrast with
the findings of Otto et al. where a diet identical to the
one used in our in vivo experiment significantly
decreased the growth of subcutaneously implanted
tumors of the gastric adenocarcinoma cell line 23132/87
[31]. The different results of the latter and our study
most likely reflect intrinsic properties of the cell lines
used. In contrast to the gastric adenocarcinoma cell line,
LNT-229 human glioma cells usually form quite
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might be more susceptible to dietary restriction, as the
necrotic areas in those tumors reflect the already limited
supply of nutrients and oxygen. Since hypoxic tumor
cells particularly depend on glucose availability [37],
limiting carbohydrates might be effective in these
tumors. The downregulation of ketone body metaboliz-
ing enzymes under hypoxic conditions observed in our
cell lines (Figure 3A) suggests an additional disadvantage
of this hypoxic tumor fraction. Another possible expla-
nation may be a differential energy supply of subcuta-
neous and intracranial tumors. The mouse brain cells
could have adapted to metabolize ketone bodies, leaving
enough glucose to meet the xenografts’ energy require-
ments. Using a different unrestricted ketogenic diet and
the GL261 syngeneic intracranial glioma mouse model,
Stafford et al. found a reduced rate of tumor growth
and prolonged survival [71]. Likewise, GL261 tumors
display necrotic zones [72]. Obviously, the impact of
ketosis and hence the results of such studies depend on
the model applied.
Conclusion
In summary, our results suggest a deficiency of glioma
cell lines to metabolize ketone bodies in vitro, support-
ing the possibility of targeting tumor energy metabolism
by a ketogenic diet. However, an unrestricted ketogenic
diet was not effective as a monotherapy in the xenograft
model applied. A combination of a ketogenic diet with
strategies inhibiting glycolysis or interfering with the
tumor’s energy supply, such as vascular disrupting or
antiangiogenic agents [73], might result in synergistic
antitumor effects and is worth further investigation.
Additional material
Additional file 1: Figure S1. The presence of 3-hydroxybutyrate does
not modify glucose consumption or lactate generation of the glioma cell
lines. U87MG, U251MG, LNT-229, T98G and A172 cells were cultured in
medium containing 5 mM glucose and 5 mM 3-hydroxybutyrate (3OHB).
Glucose and lactate concentrations of cell culture supernatants were
analyzed on days 1, 2, 3, 4, 5 and 6.
Additional file 2: Figure S2. Expression of HIF-1a target genes is not
modulated by 3-hydroxybutyrate. LNT-229 cells were either untreated or
treated with 3-hydroxybutyrate for 24 h at normoxia or hypoxia, and the
expression of the HIF-1a target genes GLUT1, VEGF or MCT4 was
analyzed by real-time quantitative PCR (fold change in gene expression
normalized to the internal control 18S rRNA; mean and standard
deviation).
Abbreviations
3OHB: 3-hydroxybutyrate; AACS: acetoacetyl-CoA synthetase; AcAc:
acetoacetate; ACAT1: acetyl-CoA acetyltransferase; BDH: 3-hydroxybutyrate
dehydrogenase; GLUT1: glucose transporter 1; HIF-1α: hypoxia-inducible
factor-1α; HRE: hypoxia responsive element; IGF-1: insulin-like growth factor
1; MCT4: monocarboxylic acid transporter 4; OXCT1: 3-oxoacid-CoA
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VEGF: vascular endothelial growth factor.
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